A Phase 1 Study of Epidermal Growth Factor Receptor (EGFR) Targeted, Paclitaxel Loaded EnGeneIC Delivery Vehicles (Erbitux®EDVsPac) in Patients with Advanced Solid Tumours
A Phase 1 Study of Epidermal Growth Factor Receptor (EGFR) Targeted, Paclitaxel Loaded EnGeneIC Delivery Vehicles in Patients with Advanced Solid Tumours
EnGeneIC Pty Ltd
32 participants
Aug 19, 2009
Interventional
Conditions
Summary
This study looks at treatment with a targeted biological therapy (Epidermal Growth Factor Receptor [EGFR] Targeted, Paclitaxel Loaded EnGeneIC Delivery Vehicles [ErbituxEDVsPac]) in people with advanced epithelial cancer. Who is it for? You can join this study if you have: – advanced epithelial cancer which has spread to secondary or distant sites or cannot be removed by surgery – a tumour type known to express EGFR. Trial details All participants will receive ErbituxEDVsPac Dose at increasing doses. The study will monitor the safety and effectiveness of treatment, in particular the immune and inflammatory response (measured after each treatment) and the tumour response (measured after each six week cycle of treatment).
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
EGFR targeted, Paclitaxel loaded EnGeneIC Delivery Vehicle (EDV) An EDV is an anucleate bacterially derived minicell. EDVs can be loaded with chemotherapy, in this case paclitaxel. The EDV is coated with EGFR antibodies to enable it to attach to cancer cells. The EDVs are administered by intravenous infusion. This is a dose escalation study with potentially 6 levels. The doses are stated as number of EDVs given. The starting dose is 1X10e8 EDVs and increasing to a maximum of 2X10e11 EDVs. Each dose is given as a 20mL injection administered slowly over a period of 20 minutes. Patients are treated in cycles of 5 infusions administered at weekly intervals, separated by a treatment free week. Patients may continue in the study if their tumor is stable or responding. Patients with progressive disease may be able to continue treatment if there are no other proven treatment options available to them
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12609000672257